Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital, b3982d)
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are multipotent stromal cells harvested from umbilical cord tissue, typically Wharton's jelly. These cells are characterized by their low immunogenicity and potent immunomodulatory, anti-inflammatory, and tissue-repair capabilities. In clinical development, particularly at the Beijing 302 Hospital (now the Fifth Medical Center of the PLA General Hospital), hUC-MSCs are being evaluated as a cell therapy for liver failure, including acute-on-chronic liver failure (ACLF). The therapeutic mechanism involves the migration of MSCs to the injured liver, where they secrete paracrine factors (such as cytokines and growth factors) that suppress hepatic inflammation, reduce hepatocyte apoptosis, and stimulate the regeneration of liver tissue. They have also shown potential in treating other immune-mediated and inflammatory conditions such as Crohn's disease, systemic lupus erythematosus, and psoriasis.
- Other names
- umbilical cord-derived mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital, b3982d).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital, b3982d).